2021-01-312021-01-312011-12-011064-74491098-0997http://dx.doi.org/10.34944/dspace/547222028586 (pubmed)http://hdl.handle.net/20.500.12613/5490Chlamydia trachomatis polymorphic membrane proteins (Pmps) may increase genital tract inflammation and play a role in virulence. Antibody levels for PmpA, PmpD, and PmpI, measured in densitometric units, were assessed among a pilot sample of 40 C. trachomatis-infected women with mild-to-moderate clinical PID. Women who expressed antibodies to PmpA were less likely to achieve pregnancy (40.0 versus 85.7; P = 0.042) and less likely to have a live birth (0.0 versus 80.0; P = 0.005) compared to women who did not express antibody to PmpA. Women who expressed antibodies to PmpI were more likely to have upper genital tract infection (61.5 versus 20.0; P = 0.026). However, seropositivity to PmpI and PmpD did not modify the risk of reproductive sequelae or inflammation. Seropositivity to chlamydial PmpA may represent a biomarker of increased risk of sequelae secondary to infection with C. trachomatis. © 2011 Brandie D. Taylor et al.1-8enCC BYhttp://creativecommons.org/licenses/by/3.0/AdultAntibodies, BacterialBacterial Outer Membrane ProteinsChlamydia InfectionsChlamydia trachomatisFemaleFertilityHumansPelvic Inflammatory DiseasePilot ProjectsPregnancyPregnancy OutcomeArticle2021-01-31